TargetBeta
F8
coagulation factor VIII · also FVIII, DXS1253E, HEMA, F8C · Multicopper oxidase family
4 programs in company-led studies act on F8, from 4 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| efanesoctocog alfarule | Sanofi | – | phase 4 | 125 running | – | NCIt |
| omfiloctocog alfarule | Sinocelltech Group | – | phase 4 | 62 running | – | ChEMBL |
| antihemophilic factor, human recombinantrule | Takeda | – | phase 4 | 161 running | – | ChEMBL |
| lonoctocog alfarule | CSL | – | phase 3 | 40 running | – | ChEMBL |
Conditions their studies are in
- Hemophilia A, 4 programs
- von Willebrand Diseases, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 17, 2026efanesoctocog alfa · Sanofi · phase 4 · NCT06752850
- Nov 25, 2027antihemophilic factor, human recombinant · Takeda · phase 4 · NCT07129343
- Dec 26, 2028omfiloctocog alfa · Sinocelltech Group · phase 4 · NCT07437404
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.